Bcl‐2 is a prognostic marker and its silencing inhibits recurrence in ameloblastomas

Abstract

Objectives

Ameloblastomas are the most common odontogenic epithelial tumors with high recurrence rate. The aim of this study is to identify apoptosis‐related genes with recurrence of ameloblastomas and to evaluate its feasibility as a prognostic marker and as a target molecule preventing from recurrence.

Materials and Methods

Public microarray data were analyzed. To evaluate their expression in ameloblastoma patients, immunohistochemical staining was performed in 89 human ameloblastoma tissues. Quantitative‐PCR was performed by use of ameloblastoma cell line, AM‐1. FACS analysis and western blotting were conducted following transfection with siRNA. Further, AM‐1 cells were implanted in the renal subcapsular layer of immunodeficient mice.

Results

Microarray data analysis revealed that Osteoprotegerin (OPG) and B‐cell lymphoma 2 (Bcl‐2) were the two most upregulated genes in ameloblastoma. Only Bcl‐2 expression was significantly (P = 0.020) associated with recurrence in conservative treatment group (n = 17) among 89 patients. Silencing of Bcl‐2 increased apoptosis in AM‐1 cells in vitro and inhibited tumor nodule formation of AM‐1 cells in vivo.

Conclusion

These results suggest that Bcl‐2 expression is a useful biomarker to predict recurrence of ameloblastomas, and as a therapeutic target molecule to prevent recurrence of ameloblastoma.

This article is protected by copyright. All rights reserved.

https://ift.tt/2GZOkKO